E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
ConditionCancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC
About this trial
The primary objective is the collection of real-world data of cancer patients treated with radiotherapy, to support radiotherapy research and to provide evidence of the role of radiation oncology in a multidisciplinary approach. This is an open ended prospective non-interventional non-therapeutic multi-cohort study.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Pathologically confirmed cancer.
Written informed consent for E²-RADIatE according to applicable legal and ethical requirements
Planned use of radiotherapy
Eligibility of the patient confirmed for at least one cohort confirmed
Disqualifiers
None
Trial population
Patient with various tumor types planned to be treated with radiation therapy
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
2,000 Participants
are grouped into 2 trial groupsGroup A: OligoCare
Group B: ReCare
Trial outcomes
Primary outcomes
1
Number of patients treated with radiotherapy enrolled in the program
Time frame
5 yearsSecondary outcomes
1
Disease free survival
Time frame
5 years2
Loco-regional control
Time frame
5 years3
Distant metastasis free survival
Time frame
5 years4
Overall survival
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov